 |
March 4, 2021 - Puma Biotechnology to Present at the Barclays Global Healthcare Conference
Read
March 2, 2021 - Puma Biotechnology to Present at the H.C. Wainwright Global Life Sciences Conference
Read
February 25, 2021 - Puma Biotechnology and Pierre Fabre Amend NERLYNX® License Agreement to Include Greater China
Read
February 25, 2021 - Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
Read
February 11, 2021 - Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2020 Financial Results
Read
January 29, 2021 - Puma Biotechnology Presents Interim Results from the Phase II SUMMIT Trial of Neratinib for EGFR Exon 18-Mutated, Metastatic Non-Small Cell Lung Cancer at WCLC 2020
Read
January 19, 2021 - Puma Biotechnology to Present at the B. Riley Oncology Investor Conference
Read
January 15, 2021 - Puma Biotechnology Presents Interim Results from the Biliary Tract Cancers Cohort of the Phase II SUMMIT “Basket” Trial of Neratinib at ASCO GI
Read
January 5, 2021 - Puma Biotechnology to Present at the J.P. Morgan Healthcare Conference
Read
January 4, 2021 - Puma Biotechnology to Present at the H.C. Wainwright VIRTUAL BioConnect Conference
Read
December 11, 2020 - Puma Biotechnology Presents Efficacy and Safety Outcomes from the
Phase III NALA Trial at the 2020 SABCS
Read
December 9, 2020 - Puma Biotechnology Presents Final Overall Survival Analysis from the Phase III ExteNET Trial at the 2020 SABCS
Read
December 9, 2020 - Puma Biotechnology Presents Updated Results from the Phase II SUMMIT Trial of Neratinib for HER2-Mutant, HR-Positive Metastatic Breast Cancer at SABCS 2020
Read
December 2, 2020 - Puma Biotechnology, Inc. Prevails Before European Patent Office Board of Appeals in Decision Upholding European Patent (EP 1848414) as Granted
Read
November 17, 2020 - Puma Biotechnology to Present Neratinib Data at the San Antonio Breast Cancer Symposium (SABCS)
Read
November 5, 2020 - Puma Biotechnology Announces Interim Results from the Phase II SUMMIT Trial of Neratinib for EGFR Exon 18 Mutated, Metastatic Non-Small Cell Lung Cancer
Read
November 5, 2020 - Puma Biotechnology Reports Third Quarter 2020 Financial Results
Read
November 3, 2020 - Puma Biotechnology to Present at the Credit Suisse 29th Annual Virtual Healthcare Conference
Read
October 22, 2020 - Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
Read
October 15, 2020 - NCCN Oncology Research Program and Puma Biotechnology, Inc. Collaborate to Study Neratinib in Various Cancers
Read
October 5, 2020 - Puma Biotechnology Announces Publication of Overall Survival Results from Phase III ExteNET Trial Evaluating Neratinib in HER2-Positive, Hormone Receptor-Positive, Early Stage Breast Cancer
Read
|
|
Upcoming Events
N/A
Past Events
Mar. 9, 2021 - H.C. Wainwright Global Life Sciences Conference
More
Mar. 11, 2021 - Barclays Global Healthcare Conference
More
Mar. 2, 2021 - Cowen and Company 41st Annual Health Care Conference
More
Feb. 25, 2021 - Puma Biotechnology 4Q-2020 Financial Results Conference Call
More
Jan. 26-29, 2021 - IASLC 2021 World Conference on Lung Cancers
More
Jan. 21, 2021 - B. Riley Oncology Investor Conference
More
Jan. 15-17, 2021 - ASCO 2021 Gastrointestinal Cancers Symposium
More
Jan. 14, 2021 - 39th Annual J.P. Morgan Healthcare Conference
More
Jan. 11, 2021 - H.C. Wainwright VIRTUAL BioConnect Conference
More
Dec. 8-11, 2020 - San Antonio Breast Cancer Symposium
More
Nov. 10, 2020 - Credit Suisse 29th Annual Virtual Healthcare Conference
More
Nov. 5, 2020 - Puma Biotechnology 3Q-2020 Financial Results Conference Call
More
Sept. 15, 2020 - H.C. Wainwright 22nd Annual Global Investment Conference.
More
|
Annual Report Archives
Puma Biotechnology, Inc.
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax
Medical Inquiries:
1-844-MED-PUMA (1-844-633-7862), or
medinfo@pumabiotechnology.com
Business Development:
info@pumabiotechnology.com
Investor Relations:
ir@pumabiotechnology.com
Follow Us:
|
